Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials

被引：1
|
作者：
Pandy, J. G. P. [1 ]
Ordinario, M. V. C. [1 ]
Alcantara, M. J. E. [1 ]
Li, R. K. [1 ]
机构：
[1] St Lukes Med Ctr, Sect Med Oncol, Dept Med, Quezon City, Philippines
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.316
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
194P
引用
收藏
页码：S320 / S320
页数：1
相关论文
共 50 条
  • [41] Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis
    Bai, Jie
    Yao, Xufeng
    Pu, Yinghong
    Wang, Xiaoyi
    Luo, Xinrong
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [42] Immunotherapy in combination with neoadjuvant anthracycline-free chemotherapy for triple-negative early breast cancer: A case report
    Zhao, Xiangwang
    Dong, Fang
    Chen, Weibin
    Liu, Chunping
    ONCOLOGY LETTERS, 2023, 26 (03)
  • [43] Efficacy of adding an immune checkpoint inhibitor to chemotherapy in the first-line treatment of metastatic triple-negative breast cancer: A meta-analysis of randomized controlled trials
    Ergun, Y.
    Kalkan, Z.
    Ileri, S.
    Tunc, S.
    Urakci, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S212 - S212
  • [44] Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer
    Denkert, Carsten
    Schneeweiss, Andreas
    Rey, Julia
    Karn, Thomas
    Hattesohl, Akira
    Weber, Karsten E.
    Rachakonda, Sivaramakrishna
    Braun, Michael
    Huober, Jens
    Jank, Paul
    Sinn, Hans-Peter
    Zahm, Dirk-Michael
    Felder, Barbel
    Hanusch, Claus
    Teply-Szymanski, Julia
    Marme, Frederik
    Fehm, Tanja
    Thomalla, Jorg
    V. Sinn, Bruno
    Stiewe, Thorsten
    Marczyk, Michal
    Blohmer, Jens-Uwe
    van Mackelenbergh, Marion
    Schem, Christian
    Staib, Peter
    Link, Theresa
    Muller, Volkmar
    Stickeler, Elmar
    Stover, Daniel G.
    Solbach, Christine
    Metzger-Filho, Otto
    Jackisch, Christian
    Geyer Jr, Charles E.
    Fasching, Peter A.
    Pusztai, Lajos
    Nekljudova, Valentina
    Untch, Michael
    Loibl, Sibylle
    CELL REPORTS MEDICINE, 2024, 5 (11)
  • [45] Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
    Lu, Fei
    Hou, Yu
    Chen, Zhengting
    Jiang, Jie
    He, Xi
    Xia, Yaoxiong
    Cao, Ke
    Chang, Li
    Li, Wenhui
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20
  • [46] Efficacy and Safety of Atezolizumab Monotherapy or Combined Therapy with Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Alimohammadi, Mina
    Faramarzi, Fatemeh
    Mafi, Alireza
    Mousavi, Tahoora
    Rahimi, Ali
    Mirzaei, Hamed
    Asemi, Zatollah
    CURRENT PHARMACEUTICAL DESIGN, 2023, 29 (31) : 2461 - 2476
  • [47] Immune checkpoint inhibitors as neoadjuvant therapy in early triple-negative breast cancer: A systematic review and meta-analysis
    Mittal, Niti
    Singh, Surjit
    Mittal, Rakesh
    Kaushal, Jyoti
    Kaushal, Vivek
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2022, 18 (06) : 1754 - +
  • [48] Pembrolizumab plus Chemotherapy for triple-negative Breast Cancer
    Judith Lorenz, Kuenzell
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (11) : 1114 - 1114
  • [49] Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis
    Cortes, J.
    Haiderali, A.
    Huang, M.
    Pan, W.
    Fox, G. E.
    Park, J.
    Frederickson, A. M.
    Fasching, P. A.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S615 - S616
  • [50] Pembrolizumab plus chemotherapy in triple-negative breast cancer
    Masuda, Jun
    Ozaki, Yukinori
    Hara, Fumikata
    Kitano, Shigehisa
    Takano, Toshimi
    LANCET, 2021, 398 (10294): : 24 - 24
12345